Thus, our data suggest that the synergistic efficacy of co-treatment with sorafenib and radiation resulted in a potential combined treatment effect for specific targeting of CD44+CD24−/low cells from breast cancer cells in vitro. This evidence concerns the gene CD44 and breast cancer.